Search results for " Metastasis."

showing 10 items of 617 documents

A Proposal for Novel Standards of Histopathology Reporting for D3 Lymphadenectomy in Right Colon Cancer: The Mesocolic Sail and Superior Right Colic …

2020

Background Strong agreement exists concerning the standards of pathologic reporting for total mesorectal excision and complete mesocolic excision. It represents a quality standard that correlates with survival. However, no agreed standards of reporting are available to define D3 lymphadenectomy for right colectomy. Objective The purpose of this study was to define anatomopathological standards of specimen quality obtained from the surgical specimen when an oncologic right hemicolectomy with D3 lymphadenectomy has been correctly performed. Design This study was conducted in 2 different phases. The first part consisted of a cadaver-based study of right colon anatomy, and the second part consi…

Malemedicine.medical_specialtySurgical specimen03 medical and health sciencesMesenteric Veins0302 clinical medicineD3 lymphadenectomyCadaverHumansMedicineD3 lymphadenectomyProspective StudiesColectomyAgedNeoplasm StagingAged 80 and overNew quality standardsbusiness.industryRight colic veinGastroenterologyOutcome measuresGeneral MedicineMiddle AgedColon cancermedicine.anatomical_structureSpecimen QualityLymphatic Metastasis030220 oncology & carcinogenesisQuality standardColonic NeoplasmsRight ColectomyLymph Node ExcisionFemaleLaparoscopy030211 gastroenterology & hepatologyHistopathologyLymph NodesAnatomic LandmarksbusinessNuclear medicineFollow-Up StudiesDiseases of the Colon & Rectum
researchProduct

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the ran…

2019

Background: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by thr…

Malemedicine.medical_specialtyTime FactorsHepatic resectionTreatment outcomeAntineoplastic Agents030230 surgeryMicrosphereClinical study03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansNeoplasm MetastasisChirurgieLiver imagingRetrospective Studiesbusiness.industryIndividual participant dataLiver NeoplasmsFollow up studiesPatient dataOriginal ArticlesMiddle AgedTreatment Outcome030220 oncology & carcinogenesisFamily medicineHPBLower GISurgeryOriginal ArticleFemaleRadiotherapy AdjuvantbusinessColorectal NeoplasmsTomography X-Ray Computed:Ciencias de la Salud::Oncología [Materias Investigacion]Follow-Up Studies
researchProduct

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

2005

OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant combined chemotherapy with methotrexate, vinblastine, doxorubicin/epirubicin, and cisplatin (MVAC/MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival. PATIENTS AND METHODS Between May 1987 and December 1990, 49 patients undergoing radical cystectomy for locally advanced bladder cancer were randomized to observation only or adjuvant systemic chemotherapy with three cycles of MVAC/MVEC (methotrexate 30 mg/m2 on day 1, 15 and 22; vinblastine 3 mg/m2 on day 2, 15 and 22; doxorubicin …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastineDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedEpirubicinChemotherapyBladder cancerbusiness.industryHazard ratioCombination chemotherapyMiddle Agedmedicine.diseaseInterim analysisCombined Modality TherapyVinblastineSurgeryMethotrexateTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinNeoplasm Recurrence Localbusinessmedicine.drugEpirubicinFollow-Up StudiesBJU international
researchProduct

Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome

2010

Management of the neck in patients treated with primary chemoradiation for cancer of the laryngopharynx with a clinically positive neck remains an area of controversy. The neck may be managed in 1 of 3 ways: by observation, by planned neck dissection, or by salvage neck dissection. Observation of the neck can be done in patients who have a complete or near-complete response to treatment and have a negative positron emission tomography (PET) scan result. Evidence for this approach comes from recent studies that have reported low regional recurrence rates.1–6 Planned neck dissection was carried out in the past in patients with N2 and N3 neck disease irrespective of the response to chemoradiat…

Malemedicine.medical_specialtymedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaPhysical examinationKaplan-Meier EstimateArticlemedicineCarcinomaHumanschemoradiationLaryngeal NeoplasmsRetrospective Studiesmedicine.diagnostic_testbusiness.industryCancerPharyngeal NeoplasmsRetrospective cohort studyNeck dissectionChemoradiotherapyMiddle AgedLaryngeal Neoplasmmedicine.diseaseSurgeryOtorhinolaryngologyviable tumorPositron emission tomographyLymphatic MetastasisCarcinoma Squamous CellNeck DissectionFemaleprognosisbusinessChemoradiotherapyFollow-Up StudiesHead & Neck
researchProduct

Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric, randomized DÖSAK study of a…

1994

Abstract A multicentric, randomized study of squamous cell carcinoma (SCC) of the oral cavity and the oropharynx has been undertaken by DOSAK. The results after radical surgery alone have been compared with the results of combined preoperative radiochemotherapy followed by radical surgery. Patients with primary (biopsy proven) SCC of the oral cavity or the oropharynx with tumor nodes metastasis (TNM) stages T2–4, N0–3, M0 were included in the study. A total of 141 patients were treated by radical surgery alone, whereas 127 patients were treated by radical surgery preceded by preoperative radiochemotherapy. The preoperative treatment consisted of conventionally fractioned irradiation on the …

Malemedicine.medical_specialtymedicine.medical_treatmentlaw.inventionMetastasisRandomized controlled triallawPreoperative CareBiopsymedicineHumansLife TablesProspective StudiesRadical surgerySurvival analysisChemotherapymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseCombined Modality TherapySurgerySurvival RateRadiation therapyLog-rank testOropharyngeal NeoplasmsOtorhinolaryngologyLymphatic MetastasisCarcinoma Squamous CellFemaleMouth NeoplasmsSurgeryCisplatinNeoplasm Recurrence LocalOral SurgerybusinessFollow-Up StudiesInternational Journal of Oral and Maxillofacial Surgery
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

Characterization of C4-2 Prostate Cancer Bone Metastases and Their Response to Castration

2003

New well-characterized preclinical models of prostate cancer (CaP) bone metastases are needed to improve our understanding of the development of CaP-related bone disease in patients. Here we describe characterization of a model consisting of direct injection of C4–2 cells into tibias. Introduction: Prostate cancer (CaP) has a high proclivity to metastasize to bone. Development and characterization of preclinical models of CaP bone metastases are of high interest. The objective of this study was to characterize C4–2 bone metastases and their response to castration. Materials and Methods: Cell suspensions of C4-2, a subline of LNCaP, were injected directly into the tibias of intact male mice.…

Malemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsBone densityBone diseaseEndocrinology Diabetes and MetabolismLong boneMice SCIDBone and BonesMicechemistry.chemical_compoundProstate cancerBone DensityCell Line TumorInternal medicineBone cellmedicineAnimalsHumansOrthopedics and Sports MedicineCastrationNeoplasm MetastasisBone mineralTibiabusiness.industryProstatic NeoplasmsBone metastasisProstate-Specific Antigenmusculoskeletal systemmedicine.diseaseCastrationmedicine.anatomical_structureEndocrinologychemistryReceptors AndrogenbusinessNeoplasm TransplantationJournal of Bone and Mineral Research
researchProduct

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

2017

Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We ident…

Mama -- Càncer -- Aspectes genètics0301 basic medicineCancer ResearchPathologyReceptor ErbB-2DiseaseTranscriptome0302 clinical medicineGene expressionSurvival outcomes Letrozole Concordance Predictor Disease Impact Brain Cells Women RiskSurvival outcomesDiseaseNeoplasm Metastasisskin and connective tissue diseasesRegulation of gene expressionAged 80 and overBrainCells WomenMiddle AgedPrognosisMetastatic breast cancerNeoplasm ProteinsGene Expression Regulation NeoplasticImpactOncology030220 oncology & carcinogenesisLetrozoleFemaleRiskAdultmedicine.medical_specialtymedicine.drug_classBreast NeoplasmsBiologyArticle03 medical and health sciencesBreast cancerConcordancemedicineBiomarkers TumorHumansGeneAgedEstrogensmedicine.disease030104 developmental biologyEstrogenNeoplasm Recurrence LocalTranscriptomePredictor
researchProduct

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct